Vigil is the first cellular immunotherapy to demonstrate longer-term survival benefits in a randomized controlled trial of patients with solid tumors. The results of the company's Phase 2b study have ...

For more information on the Phase 1b clinical trial, visit: https://clinicaltrials.gov/study/NCT06732180 ...

Japan’s Shionogi (TYO: 4507) yesterday delivered a late-breaking scientific oral presentation at the Conference of ...

INVINCIBLE-3 Study, and 25 patients have been screened Eight Swiss sites are activated in the INVINCIBLE-4 Study, and several ...

Sorghum is an increasingly important crop for animal and human nutrition, especially in arid and semi-arid regions, due to ...

In a series of three recent studies, a team led by CSIC researcher at CRAG Ana I. Caño-Delgado has made significant progress ...

Check about porn addiction symptoms, how it affects your mind, and its impact on relationships, time, finances, and overall ...

KOCHI: An expert committee formed by the Kerala government to study the issues faced by Fair Price Shop (FPS) dealers has proposed significant changes to the st ...

Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...

Learn more about whether ACADIA Pharmaceuticals Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...

Findings from a pair of studies in tough-to-treat hypertension establish Mineralys’ drug as a “derisked, almost-commercial ...

Interim Results from clinical study for cutaneous carcinomas presented at Late-Breaking Research SessionMarlborough, Massachusetts--(Newsfile ...